Pharmacokinetic analysis and optimization of hydroxycamptothecin-loaded nanoparticles for liver targeting

Drug Development and Industrial Pharmacy

Volumn 38, Issue 7, 2012, Pages 837-847

  Li, Yimu ^a   Wei, Pei ^a   Li, Jin ^a   Li, Lingbing ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Hydroxypropyl cyclodextrins; Liver targeting; Nanoparticles; Pharmacokinetic model; Poly(butylcyanoacrylate)

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; HYDROXYCAMPTOTHECIN; NANOPARTICLE; POLY(BUTYLCYANOACRYLATE); UNCLASSIFIED DRUG; ENBUCRILATE; HYDROXYCAMPTOTHECIN POLYBUTYLCYANOACRYLATE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG RELEASE; DRUG TARGETING; FEMALE; IN VITRO STUDY; LIVER; MALE; NONHUMAN; PARTICLE SIZE; RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; SOLUBILITY; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG DELIVERY SYSTEMS; ENBUCRILATE; FEMALE; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; RATS; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 84861496724     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.630393     Document Type: Article

References (23)

1. Chen LC, Chang CH, Yu CY, Chang YJ, Hsu WC, Ho CL et al. (2007). Biodistribution, pharmacokinetics and imaging of (188) Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol, 34:415-423.
2. Park JH, Saravanakumar G, Kim K, Kwon IC. (2010). Targeted delivery of low molecular drugs using chitosan and its derivatives. Adv Drug Deliv Rev, 62:28-41.
3. Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. (2000). Liposomal encapsulation of topotecan enhances anticancer efcacy in murine and human xenograft models. Cancer Res, 60:3389-3393.
4. Barreiro-Iglesias R, Bromberg L, Temchenko M, Hatton TA, Concheiro A, Alvarez-Lorenzo C. (2004). Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J Control Release, 97:537-549.
5. Jang JH, Kim CK, Choi HG, Sung JH. (2009). Preparation and evaluation of 2-(allylthio)pyrazine-loaded lipid emulsion with enhanced stability and liver targeting. Drug Dev Ind Pharm, 35:363-368.
6. Lin A, Chen J, Liu Y, Deng S, Wu Z, Huang Y et al. (2009). Preparation and evaluation of N-caproyl chitosan nanoparticles surface modifed with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm, 35:1348-1355.
7. Hall JB, Dobrovolskaia MA, Patri AK, McNeil SE. (2007). Characterization of nanoparticles for therapeutics. Nanomedicine (Lond), 2:789-803.
8. De Jong WH, Hagens WI, Krystek P, Burger MC, Sips AJ, Geertsma RE. (2008). Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials, 29:1912-1919.
9. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. (2008). Factors afecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm, 5:505-515.
10. Kutscher HL, Chao P, Deshmukh M, Sundara Rajan S, Singh Y, Hu P et al. (2010). Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int J Pharm, 402:64-71.
11. Calvo P, Gouritin B, Chacun H, Desmaële D, D'Angelo J, Noel JP et al. (2001). Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res, 18:1157-1166.
12. Vauthier C, Dubernet C, Fattal E, Pinto-Alphandary H, Couvreur P. (2003). Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev, 55:519-548.
13. Stella VJ, Rajewski RA. (1997). Cyclodextrins: Teir future in drug formulation and delivery. Pharm Res, 14:556-567.
14. Bibby DC, Davies NM, Tucker IG. (2000). Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm, 197:1-11.
15. Leroy-Lechat F, Wouessidjewe D, Andreux JP, Puisieux F, Duchêne, D. (1994). Evaluation of the toxicity of cyclodextrins and hydroxypropylated derivatives. Int J Pharm, 101:97-103.
16. Li SD, Huang L. (2008). Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm, 5:496-504.
17. Tong W, Wang L, D'Souza MJ. (2003). Evaluation of PLGA microspheres as delivery system for antitumor agent-camptothecin. Drug Dev Ind Pharm, 29:745-756.
18. Mu L, Elbayoumi TA, Torchilin VP. (2005). Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin. Int J Pharm, 306:142-149.
19. Duchêne D, Ponchel G, Wouessidjewe D. (1999). Cyclodextrins in targeting. Application to nanoparticles. Adv Drug Deliv Rev, 36:29-40.
20. Schoemaker NE, Frigerio E, Fraier D, Schellens JH, Rosing H, Jansen S et al. (2001). High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma. J Chromatogr B Biomed Sci Appl, 763:173-183.
21. Yang L, Cui F, Cun D, Tao A, Shi K, Lin W. (2007). Preparation, characterization and biodistribution of the lactone form of 10- hydroxycamptothecin (HCPT)-loaded bovine serum albumin (BSA) nanoparticles. Int J Pharm, 340:163-172.
22. Nishikawa M, Takakura Y, Hashida M. (2005). Teoretical considerations involving the pharmacokinetics of plasmid DNA. Adv Drug Deliv Rev, 57:675-688.
23. Li L, Wei P, Liu J. (2009). [Study on pharmacokinetics model for targeted drug delivery systems]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, 26:526-529.